0byt3m1n1-V2
Path:
/
home
/
nlpacade
/
www.OLD
/
arcaneoverseas.com
/
79995o83
/
cache
/
[
Home
]
File: 3405fc82a4bdd096303eae52f3c164d4
a:5:{s:8:"template";s:10119:"<!DOCTYPE html> <html lang="en"> <head> <meta charset="utf-8"/> <title>{{ keyword }}</title> <link href="//fonts.googleapis.com/earlyaccess/notokufiarabic" id="notokufiarabic-css" media="all" rel="stylesheet" type="text/css"/> </head> <style rel="stylesheet" type="text/css">@charset "UTF-8";html{-ms-touch-action:manipulation;touch-action:manipulation;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}footer,header,nav{display:block}a{background-color:transparent}a:active,a:hover{outline-width:0}*{padding:0;margin:0;list-style:none;border:0;outline:0;box-sizing:border-box}:after,:before{box-sizing:border-box}body{background:#f7f7f7;color:#2c2f34;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue","Open Sans",sans-serif;font-size:13px;line-height:21px}a{color:#333;text-decoration:none;transition:.15s}a:hover{color:#08f}::-moz-selection{background:#08f;color:#fff;text-shadow:none}::selection{background:#08f;color:#fff;text-shadow:none}.button.guest-btn:not(:hover){color:#2c2f34}.background-overlay{background-attachment:fixed}.blocks-title-style-4 .widget-title a:not(:hover){color:#fff}.blocks-title-style-7 #tie-wrapper .widget-title a:not(:hover){color:#fff}.blocks-title-style-8 .mag-box .mag-box-title h3 a:not(:hover){color:inherit}.screen-reader-text{clip:rect(1px,1px,1px,1px);position:absolute!important;height:1px;width:1px;overflow:hidden}.autocomplete-suggestions.live-search-dark .post-title a:not(:hover){color:#fff}.autocomplete-suggestions.live-search-light .post-title a:not(:hover){color:#2c2f34}.autocomplete-suggestion.live-search-dark .post-title a:not(:hover){color:#fff}.autocomplete-suggestions.live-search-popup .post-title a:not(:hover){color:#fff}.dark-skin .tie-slider-nav li span:not(:hover){color:#aaa;border-color:rgba(0,0,0,.1)}.pages-nav .next-prev a:not(:hover),.pages-nav .pages-numbers a:not(:hover){color:#2c2f34}#breadcrumb a:not(:hover){color:#999}#main-nav .components>li.social-icons-item .social-link:not(:hover) span,#top-nav .components>li.social-icons-item .social-link:not(:hover) span{color:#2c2f34}ul:not(.solid-social-icons) .social-icons-item a:not(:hover){background-color:transparent!important}a.remove.light-btn:not(:hover):before{color:#fff}.tie-alignleft{float:left}#tie-wrapper,.tie-container{height:100%;min-height:650px}.tie-container{position:relative;overflow:hidden}#tie-wrapper{background:#fff;position:relative;z-index:108;height:100%;margin:0 auto}#content{margin-top:30px}@media (max-width:991px){#content{margin-top:15px}}.site-content{-ms-word-wrap:break-word;word-wrap:break-word}.boxed-layout #tie-wrapper{max-width:1230px}@media (min-width:992px){.boxed-layout #tie-wrapper{width:95%}}#theme-header{background:#fff;position:relative;z-index:999}#theme-header:after{content:"";display:table;clear:both}.logo-row{position:relative}.logo-container{overflow:hidden}#logo{margin-top:40px;margin-bottom:40px;display:block;float:left}#logo a{display:inline-block}@media (max-width:991px){#theme-header #logo{margin:10px 0!important;text-align:left;line-height:1}}.main-nav-dark #main-nav .comp-sub-menu a:not(:hover),.top-nav-dark #top-nav .comp-sub-menu a:not(:hover){color:#fff}.main-nav-dark #main-nav .comp-sub-menu a.checkout-button:not(:hover),.top-nav-dark #top-nav .comp-sub-menu a.checkout-button:not(:hover){color:#fff}.top-nav-dark #top-nav .comp-sub-menu .button.guest-btn:not(:hover){background:#1f2024;border-color:#1f2024}#top-nav a:not(.button):not(:hover){color:#2c2f34}.top-nav-dark #top-nav .breaking a:not(:hover),.top-nav-dark #top-nav .breaking-news-nav a:not(:hover){color:#aaa}.top-nav-dark #top-nav .components>li.social-icons-item .social-link:not(:hover) span{color:#aaa} .main-nav-wrapper{display:none}.main-menu-wrapper .tie-alignleft{width:100%}}.light-skin #mobile-social-icons .social-link:not(:hover) span{color:#777!important}.post-meta a:not(:hover){color:#777}.big-thumb-left-box .posts-items li:first-child .post-meta a:not(:hover),.miscellaneous-box .posts-items li:first-child .post-meta a:not(:hover){color:#fff}.box-dark-skin .mag-box-options .mag-box-filter-links li a:not(:hover),.dark-skin .mag-box .mag-box-options .mag-box-filter-links li a:not(:hover){color:#aaa}.entry-header .post-meta a:not(:hover){color:#333}.single-big-img .post-meta a:not(:hover){color:#fff}.about-author .social-icons li.social-icons-item a:not(:hover) span{color:#2c2f34}.multiple-post-pages a:not(:hover){color:#2c2f34}.post-content-slideshow .tie-slider-nav li span:not(:hover){background-color:transparent}.login-widget .forget-text:not(:hover){color:#2c2f34}.post-tags a:not(:hover),.widget_layered_nav_filters a:not(:hover),.widget_product_tag_cloud a:not(:hover),.widget_tag_cloud a:not(:hover){color:#2c2f34}.dark-skin .latest-tweets-widget .slider-links .tie-slider-nav li span:not(:hover){background-color:transparent}.main-slider .thumb-meta .post-meta a:not(:hover){color:#fff}.main-slider .thumb-meta .post-meta a:not(:hover):hover{opacity:.8}#tie-wrapper:after{position:absolute;z-index:1000;top:-10%;left:-50%;width:0;height:0;background:rgba(0,0,0,.2);content:'';opacity:0;cursor:pointer;transition:opacity .5s,width .1s .5s,height .1s .5s}#footer{margin-top:50px;padding:0}@media (max-width:991px){#footer{margin-top:30px}}#site-info{background:#161619;padding:20px 0;line-height:32px;text-align:center}.dark-skin{background-color:#1f2024;color:#aaa}.dark-skin .pages-nav .next-prev a:not(:hover),.dark-skin .pages-nav .pages-numbers a:not(:hover),.dark-skin .single-big-img .post-meta a:not(:hover),.dark-skin a:not(:hover){color:#fff}.dark-skin #mobile-menu-icon:not(:hover) .menu-text,.dark-skin .about-author .social-icons li.social-icons-item a:not(:hover) span,.dark-skin .login-widget .forget-text:not(:hover),.dark-skin .multiple-post-pages a:not(:hover),.dark-skin .post-meta a:not(:hover){color:#aaa}.dark-skin .latest-tweets-slider-widget .latest-tweets-slider .tie-slider-nav li a:not(:hover){border-color:rgba(255,255,255,.1)}.dark-skin .boxed-five-slides-slider li:not(.slick-active) button:not(:hover),.dark-skin .boxed-four-taller-slider li:not(.slick-active) button:not(:hover),.dark-skin .boxed-slider-three-slides-wrapper li:not(.slick-active) button:not(:hover){background-color:rgba(255,255,255,.1)}.dark-skin .widget a:not(:hover),.dark-skin .widget-title a:not(:hover){color:#fff}.container{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}.container:after,.container:before{content:" ";display:table}.container:after{clear:both}@media (min-width:768px){.container{width:100%}}@media (min-width:992px){.container{width:100%}}@media (min-width:1200px){.container{max-width:1200px}}.tie-row{margin-left:-15px;margin-right:-15px}.tie-row:after,.tie-row:before{content:" ";display:table}.tie-row:after{clear:both}.tie-col-md-12,.tie-col-md-4{position:relative;min-height:1px;padding-left:15px;padding-right:15px}@media (min-width:992px){.tie-col-md-12,.tie-col-md-4{float:left}.tie-col-md-4{width:33.33333%}.tie-col-md-12{width:100%}} .fa{display:inline-block;font:normal normal normal 14px/1 FontAwesome;font-size:inherit;text-rendering:auto;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.fa-align-left:before{content:"\f036"}@media print{body,html{background-color:#fff;color:#000;margin:0;padding:0}li,ul{page-break-inside:avoid}.single-big-img .entry-header .post-meta a:not(:hover){color:#000;text-shadow:unset}}body{visibility:visible!important}@media (min-width:992px){.tie-col-md-12,.tie-col-md-4{float:right}}.tie-alignleft{float:right}html{direction:rtl}#logo{float:right}@media (min-width:992px){.main-menu,.main-menu ul li{float:right}#theme-header .menu li.menu-item-has-children>a:before{left:12px;right:auto}}@media (max-width:991px){#theme-header #logo{text-align:right}}</style> <body class="rtl boxed-layout blocks-title-style-1 magazine1 is-thumb-overlay-disabled is-desktop is-header-layout-3 full-width hide_share_post_top hide_share_post_bottom wpb-js-composer js-comp-ver-5.1 vc_responsive" id="tie-body"> <div class="background-overlay"> <div class="site tie-container" id="tie-container"> <div id="tie-wrapper"> <header class="header-layout-3 main-nav-dark main-nav-below main-nav-boxed mobile-header-default" id="theme-header"> <div class="container"> <div class="tie-row logo-row"> <div class="logo-wrapper"> <div class="tie-col-md-4 logo-container"> <div id="logo" style="margin-top: 20px; margin-bottom: 20px;"> <a href="#" title="ADD"> {{ keyword }} </a> </div> </div> </div> </div> </div> <div class="main-nav-wrapper"> <nav class="" id="main-nav"> <div class="container"> <div class="main-menu-wrapper"> <div id="menu-components-wrap"> <div class="main-menu main-menu-wrap tie-alignleft"> <div class="main-menu" id="main-nav-menu"><ul class="menu" id="menu-tielabs-main-single-menu" role="menubar"><li aria-expanded="false" aria-haspopup="true" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-975 menu-item-has-icon is-icon-only" id="menu-item-975" tabindex="0"><a href="#"> <span aria-hidden="true" class="fa fa-align-left"></span> <span class="screen-reader-text"></span></a> <ul class="sub-menu menu-sub-content"> <li class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1039" id="menu-item-1039"><a href="#">Home</a></li> <li class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1040" id="menu-item-1040"><a href="#">About</a></li> <li class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1041" id="menu-item-1041"><a href="#">Contacts</a></li> </ul> </li> </ul></div> </div> </div> </div> </div> </nav> </div> </header> <div class="site-content container" id="content"> <div class="tie-row main-content-row"> {{ text }} <br> {{ links }} </div> </div> <footer class="site-footer dark-skin" id="footer"> <div class="" id="site-info"> <div class="container"> <div class="tie-row"> <div class="tie-col-md-12"> {{ keyword }} 2021 </div> </div> </div> </div> </footer> </div> </div> </div> </body> </html>";s:4:"text";s:9120:"Listing a study does not mean it has been evaluated by the U.S. Federal Government. Bempedoic acid is used together with lifestyle changes (diet, weight-loss, exercise) and certain cholesterol-lowering medications (HMG-CoA reductase inhibitors [statins]) to further decrease low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in the blood of adults with familial heterozygous hypercholesterolemia (HeFH; an inherited condition in which cholesterol cannot be ⦠We review the impact of bempedoic acid treatment on lipoprotein metabolism and atherosclerosis in preclinical models and patients with hypercholesterolemia. Bempedoic acid comes as a tablet to take by mouth. Although rodent studies suggested potential effects of ACL inhibition on both fatty acid and cholesterol synthesis, studies in humans show an effect only on cholesterol synthesis. Notably, the formulations herein provide pharmaceutical compositions having excellent stability and release properties for both drug products. Inhibiting ACL with bempedoic acid complements It is an inhibitor of adenosine triphosphate citrate lyase, a cellular enzyme responsible for the production of precursors for the synthesis of fatty acids and cholesterol. Bempedoic acid is a new drug that reduces cholesterol synthesis via inhibiting ATP citrate lyase. Bempedoic acid is the active ingredient in NEXLETOL, as well as the main component of NEXLIZET (in addition to ezetimibe). Structure, properties, spectra, suppliers and links for: bempedoic acid, 738606-46-7. Bempedoic acid is an adenosine triphosphate citrate lyase (ACL) inhibitor which inhibits cholesterol synthesis in the liver, thereby lowering LDL-cholesterol. Get emergency medical help if you have signs of an allergic reaction: hives, rash, severe itching, skin redness or swelling; wheezing, difficult breathing, feeling light-headed; fast or pounding heartbeats; swelling of your face, lips, tongue, or throat.. It is usually taken once a day with or without food. Bempedoic acid was approved for use in the European Union in April 2020, and the combination bempedoic acid/ezetimibe was approved in March 2020. Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used as an adjunct with diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. Tendon rupture occurred within weeks to months of starting bempedoic acid. View All Manufacturers & Suppliers of Bempedoic Acid API with Drug Master Files (DMF), CEP/COS, Japanese DMFs, Written Confirmation (WC) details listed on PharmaCompass.com The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application . It works along the cholesterol biosynthesis pathway, 2 steps upstream from the primary target of statins. following a full submission: bempedoic acid (Nilemdo®) is not recommended for use within NHSScotland. Bempedoic acid is administered orally once a day, is quickly absorbed in the small intestine, and has a half-life ranging from 15 to 24 hours . Esperion Confirms NEXLETOL⢠(bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER. It is a combination of bempedoic acid ⦠The U.S. Food and Drug Administration (FDA) granted the approval of Nexletol to Esperion Therapeutics. Bempedoic acid reduces the synthesis of cholesterol in the liver cells Tendon rupture may occur more frequently in patients over 60 years of age, Pharmacodynamics. N2 - Background: Bempedoic acid is a novel adenosine triphosphate (ATP) citrate lyase inhibitor shown to reduce low density lipoprotein cholesterol (LDL-C) when used as an adjunct lipidlowering therapy in patients with high cardiovascular disease (CVD) risk. Data sources include IBM Watson Micromedex (updated 2 Feb 2021), Cerner Multum⢠(updated 3 Feb 2021), ⦠Bempedoic acid inhibits the synthesis of cholesterol in the liver, reducing LDL-C levels. PURPOSE OF REVIEW: Bempedoic acid has emerged as a potent inhibitor of ATP-citrate lyase (ACLY), a target for the reduction of LDL cholesterol (LDL-C). Take bempedoic acid at around the same time every day. We review the impact of bempedoic acid treatment on lipoprotein metabolism and atherosclerosis in preclinical models and patients with hypercholesterolemia. Tendon Rupture: Bempedoic acid, a component of NEXLIZET, is associated with an increased risk of tendon rupture, most commonly involving the biceps tendon, rotator cuff, or Achilles tendon. bempedoic acid on cardiovascular morbidity and mortality has not been determined. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. In February 2020, bempedoic acid was approved for use in the United States. Bempedoic acid provides us with the first orally administered drug in the class of the ACLY inhibitors. So, it cannot be recommended. Bempedoic Acid ETC-1002, ESP-55016 CAS 738606-46-7 C19H36O5 MW 344.486 Da 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 8-Hydroxy-2.2.14,14-tetramethylpentadecanedioic acid ATP Citrate Lyase Inhibitor and AMP-activated Protein kinase (AMPK) activator Indication: Hypercholesterolemia Development Stage: Phase II Developer: Esperion Therapeutics Esperion ⦠The cost-effectiveness estimates for bempedoic acid with ezetimibe are not what NICE normally considers an acceptable use of NHS resources. Indication under review: in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:. It is an oral medication, intended to be taken once daily. Bempedoic acid was not teratogenic or toxic to embryos or foetuses in pregnant rabbits at doses up to 80 mg/kg/day or 12 times the systemic exposure in humans at 180 mg. Purpose of review: Bempedoic acid has emerged as a potent inhibitor of ATP-citrate lyase (ACLY), a target for the reduction of LDL cholesterol (LDL-C). Bempedoic acid is a pro-drug activated specifically within the liver where it inhibits ACL, a regulatory checkpoint within the cholesterol biosynthesis pathway. Take bempedoic acid exactly as directed. Inhibition of ACLY reduces the conversion of citrate to acetyl-CoA which is the substrate for both cholesterol and fatty acid synthesis. Bempedoic acid inhibits the synthesis of cholesterol in the liver, reducing LDL-C levels. It works by reducing the amount of cholesterol made by the liver. This reduces the development of atherosclerotic plaques that may increase the risk of cardiovascular events. Bempedoic acid (ETC-1002) is one such novel cholesterol-lowering drug. Learn about side effects, costs, and more. Zetia (ezetimibe) Nexlizet (containing bempedoic acid, ezetimibe) What are these meds used for? Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. And more people stopped taking the new drug because of side-effects than people in the dummy pill group. The application submitted is composed of administrative information, complete quality data, non - Bempedoic acid and ezetimibe side effects. LDL-C levels were lowered by 22% in the bempedoic acid arm and no reduction was seen in the placebo arm (p<0.0001). required. Nexlizet (bempedoic acid/ezetimibe) is a prescription tablet used to lower LDL (âbadâ) cholesterol in certain people. Bempedoic acid is an oral pro-drug, activated in the liver to inhibit ATP-citrate lyase (ACL), which acts upstream of HMG-CoA reductase. This upregulates LDL-R, increasing LDL-C clearance. Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents. Bempedoic acid is the only ACL inhibitor, with an innovative mechanism of action complementary to statins. Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Hypercholesterolemia or Mixed Dyslipidemia (MILOS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. This study systematically reviewed the efficacy and safety of bempedoic acid monotherapy or combination togethers in hypercholesterolemic patients. By inhibiting ACL, bempedoic acid reduces cholesterol synthesis in liver cells and triggers compensatory LDL receptor upregulation. It remains unclear whether the combination of bempedoic acid and other lipid-lowering drugs is better than these drugs alone. bempedoic acid with ezetemibe may not be as effective at reducing LDL-C levels as alirocumab or evolocumab. ";s:7:"keyword";s:18:"bempedoic acid moa";s:5:"links";s:1033:"<a href="http://arcaneoverseas.com/79995o83/deltac-slingshot-ar-15-muzzle-brake-brk116-e286bb">Deltac Slingshot Ar-15 Muzzle Brake Brk116</a>, <a href="http://arcaneoverseas.com/79995o83/dpi-test-dubai-mina-rashid-e286bb">Dpi Test Dubai Mina Rashid</a>, <a href="http://arcaneoverseas.com/79995o83/mosquito-sound-high-pitch-e286bb">Mosquito Sound High Pitch</a>, <a href="http://arcaneoverseas.com/79995o83/razer-compatible-keycaps-e286bb">Razer Compatible Keycaps</a>, <a href="http://arcaneoverseas.com/79995o83/1879-speech-to-congress-chief-joseph-summary-e286bb">1879 Speech To Congress Chief Joseph Summary</a>, <a href="http://arcaneoverseas.com/79995o83/budget-for-exhibition-e286bb">Budget For Exhibition</a>, <a href="http://arcaneoverseas.com/79995o83/best-toaster-consumer-reports-e286bb">Best Toaster Consumer Reports</a>, <a href="http://arcaneoverseas.com/79995o83/ox-tongue-spear-e286bb">Ox Tongue Spear</a>, <a href="http://arcaneoverseas.com/79995o83/where-to-buy-papalo-seeds-e286bb">Where To Buy Papalo Seeds</a>, ";s:7:"expired";i:-1;}
©
2018.